Ocular Tumor Management

Introduction

A diagnosis of a tumor in or around the eye can feel uniquely frightening. Vision shapes how you read, recognise faces, work, and move through the world, and the worry of losing it — or of losing the eye itself — sits alongside the more familiar worries of any cancer diagnosis. If you or someone in your family has been told there is an eye tumor, these concerns are natural and shared by almost every patient who walks into an ocular oncology clinic.

The encouraging reality is that ocular tumor management has changed substantially over the last two decades. Many eye tumors can now be treated in ways that preserve the eye, and in a meaningful number of cases preserve useful vision as well. Treatment combines microsurgery, targeted radiation, laser therapies, freezing techniques, and systemic drug treatment, all chosen carefully according to the type of tumor, where it sits in the eye, how large it is, and whether it has spread.

This guide explains what ocular tumor management involves, the main tumor types it addresses, the treatment options available, what recovery looks like, and how long-term follow-up is organised. It is written for adult patients who have been diagnosed with an eye or orbital tumor, and for parents of children with retinoblastoma or other paediatric eye tumors who are planning the next phase of care.

What Is Ocular Tumor Management?

Ocular tumor management is the umbrella term for diagnosing, treating, and monitoring tumors that arise in or around the eye. It is a sub-specialty of both ophthalmology and oncology sometimes called ocular oncology and it sits at the intersection of several disciplines: ophthalmic surgery, radiation oncology, medical oncology, paediatric oncology, oculoplastic and reconstructive surgery, and pathology.

• The retina — the light-sensing layer at the back of the eye (for example, retinoblastoma in children)
• The uvea — the middle vascular layer, which includes the choroid, ciliary body, and iris (uveal melanoma is the most common adult primary intraocular cancer)
• The conjunctiva — the clear membrane covering the white of the eye (conjunctival melanoma, squamous cell carcinoma, lymphoma)
• The eyelid — (basal cell carcinoma, sebaceous gland carcinoma, squamous cell carcinoma)
• The orbit — the bony socket around the eye, including muscles, fat, and the optic nerve
• The optic nerve and surrounding structures

Tumors found in the eye may be primary (starting there) or secondary (a metastasis from cancer elsewhere in the body, such as breast or lung cancer). They may be malignant (cancerous) or benign (non-cancerous), and even benign tumors sometimes need treatment if they threaten vision or grow in dangerous locations.

The goals of ocular tumor management are, in order of priority:

1. Save the patient’s life by controlling the cancer and preventing spread
2. Save the eye when this is possible without compromising the first goal
3. Preserve useful vision when this is possible without compromising the first two goals

Different tumors, and different stages of the same tumor, sit differently against these priorities. An ocular oncology team works with you to find the balance that fits your specific situation.

How Ocular Tumor Management Works

There is no single treatment for “eye cancer.” The right plan depends on what the tumor is, where it is, how big it is, how aggressively it is behaving, and whether it has affected vision or spread beyond the eye.

In practice, the treatment plan is built around one or more of the following modalities, often combined:

• Local surgery to remove the tumor while preserving the eye
• Plaque brachytherapy — a small radioactive disc stitched onto the outside of the eye over the tumor for a few days
• External beam radiation, including proton beam therapy where available
• Laser therapy (transpupillary thermotherapy, photocoagulation)
• Cryotherapy — controlled freezing of the tumor
• Chemotherapy, delivered systemically, into the eye (intravitreal), or selectively into the eye’s blood supply (intra-arterial)
• Targeted therapy and immunotherapy, especially for advanced or metastatic disease
• Enucleation (removal of the eye) when other approaches cannot safely control the tumor
• Orbital exenteration (removal of the eye and surrounding orbital contents) in rare, very advanced cases
• Active surveillance — close monitoring without immediate treatment for certain small or slow-growing lesions

A treatment plan often uses more than one of these modalities in sequence or together. For example, a child with retinoblastoma may receive systemic chemotherapy followed by laser and cryotherapy to consolidate the response. An adult with uveal melanoma may have plaque brachytherapy as the main treatment and laser therapy to address residual disease. A patient with eyelid skin cancer may have surgical excision followed by reconstructive surgery.

Who Receives Ocular Tumor Management?

Ocular tumor management is offered to people of all ages who have been diagnosed with a tumor in or around the eye. The most common groups include:

Children with Retinoblastoma

Retinoblastoma is the most common eye cancer in children, usually diagnosed before the age of five. It may affect one eye or both. Some cases are inherited through a faulty RB1 gene, which is why genetic counselling is part of standard care.

Adults with Uveal Melanoma

Uveal melanoma is the most common primary cancer that begins inside the adult eye. It arises from pigment-producing cells in the choroid, ciliary body, or iris. It is different from skin melanoma in its biology and behaviour, though both arise from melanocytes.

Patients with Conjunctival Tumors

These include conjunctival melanoma, ocular surface squamous neoplasia (a spectrum that includes squamous cell carcinoma), and conjunctival lymphoma. They often appear as visible growths on the surface of the eye.

Patients with Eyelid Tumors

Skin cancers of the eyelid — basal cell carcinoma, squamous cell carcinoma, and sebaceous gland carcinoma — are among the most common eye-area cancers in adults, particularly with cumulative sun exposure.

Patients with Ocular or Orbital Lymphoma

Lymphoma can involve the eye or orbit either as part of systemic lymphoma or as a primary disease. Treatment usually involves oncology coordination beyond the eye itself.

Patients with Orbital Tumors

Tumors of the orbit can be benign (such as cavernous haemangiomas) or malignant (such as rhabdomyosarcoma in children or metastatic disease in adults).

Patients with Metastatic Disease in the Eye

The choroid is the most common site of metastatic cancer in the eye, usually from breast cancer in women and lung cancer in men. Treatment in this setting forms part of the wider cancer plan.

Diagnosis and Pre-Treatment Evaluation

Many patients reading this article have already been through some of these tests. The full evaluation before treatment begins typically includes:

• Comprehensive ophthalmic examination, including dilated fundoscopy to look at the back of the eye
• Slit-lamp examination for tumors on or near the front of the eye
• Ocular ultrasound (B-scan) to measure tumor size and look at internal structure — particularly useful for choroidal melanoma
• Optical coherence tomography (OCT) — a non-invasive scan that produces detailed cross-sectional images of the retina
• Fluorescein and indocyanine green angiography — dye-based imaging of the eye’s blood vessels
• MRI of the orbit and brain, especially for retinoblastoma and orbital tumors
• CT scan in selected cases, particularly for bony involvement
• Biopsy — not always needed for intraocular tumors, where imaging is often diagnostic, but routinely used for conjunctival, eyelid, and orbital tumors
• Systemic staging to check for spread — usually liver imaging for uveal melanoma, full-body imaging for lymphoma, and bone-marrow studies where indicated
• Genetic testing, particularly for retinoblastoma (RB1 gene) and uveal melanoma (where chromosome 3 status and gene expression profiling carry prognostic information)

Visual acuity and intraocular pressure are checked at every stage. For children, examinations are often done under anaesthesia because cooperation is limited and detail matters.

Types and Subtypes of Treatment

Local Tumor Surgery

Where a tumor is small, accessible, and not extensively infiltrating, surgical removal can sometimes be done while keeping the eye. Techniques include:

• Local excision of conjunctival or eyelid tumors, often with a margin of healthy tissue, sometimes followed by reconstruction
• Partial lamellar sclerouvectomy — a specialised microsurgical procedure used for selected iris or ciliary body tumors
• Vitrectomy-based approaches for certain intraocular biopsies and selected interventions

Plaque Brachytherapy

Plaque brachytherapy is one of the most established eye-sparing treatments for uveal melanoma and selected retinoblastoma cases. A small dish-shaped device loaded with radioactive seeds (commonly Ruthenium-106 or Iodine-125) is stitched onto the outside of the eye, directly over the tumor location. It stays in place for several days, delivering a focused dose of radiation, and is then removed in a second short procedure.

The Collaborative Ocular Melanoma Study, a large clinical trial, helped establish that for medium-sized choroidal melanomas, plaque brachytherapy provides survival outcomes comparable to enucleation while allowing the eye to be preserved. It has shaped current uveal melanoma management worldwide.

External Beam Radiation and Proton Beam Therapy

External radiation is used for some orbital and conjunctival tumors and for ocular lymphoma. Proton beam therapy, which delivers radiation with very tight precision, is used for selected uveal melanomas, particularly tumors close to the optic nerve where plaque placement is difficult. Availability of proton therapy is limited to specialised centres.

Laser Therapy

Laser treatment uses focused light to destroy tumor tissue. Two main approaches are used in ocular oncology:

• Transpupillary thermotherapy (TTT) — gentle, prolonged heating of the tumor, often as a consolidation treatment after radiation or in selected small tumors
• Laser photocoagulation — more intense, used for very small retinal tumors and certain retinoblastoma lesions

Cryotherapy

Controlled freezing of the tumor is used for small peripheral retinal tumors (including retinoblastoma) and for some conjunctival lesions. A freezing probe is applied to the outside of the eye over the tumor and triggers tissue destruction without large incisions.

Chemotherapy

Chemotherapy plays a central role for some eye tumors:

• Systemic chemotherapy is used for retinoblastoma and for systemic lymphoma involving the eye
• Intra-arterial chemotherapy — chemotherapy delivered through a fine catheter into the ophthalmic artery that supplies the eye — is used for retinoblastoma in specialised centres and concentrates the drug at the tumor while reducing whole-body side effects
• Intravitreal chemotherapy — injecting chemotherapy directly into the eye — is used for retinoblastoma with vitreous seeding
• Topical chemotherapy (eye drops) is used for some ocular surface tumors

Targeted Therapy and Immunotherapy

For advanced uveal melanoma that has spread, newer treatments such as tebentafusp (a T-cell engager approved for HLA-A*02:01 positive metastatic uveal melanoma) and checkpoint inhibitor immunotherapy may be considered. Eligibility depends on tumor biology, genetic markers, and availability. Decisions are made together with medical oncology.

Enucleation

Enucleation is the surgical removal of the eyeball. It is offered when a tumor cannot safely be controlled while keeping the eye — for example, very large intraocular tumors, tumors that have caused total vision loss with pain, or tumors at high risk of spreading if not removed. After enucleation, an orbital implant (often made of porous material) is placed to maintain the volume of the socket. A custom-made prosthetic eye is fitted several weeks later, once healing is complete. A well-made prosthesis matches the other eye closely in appearance and moves with the surrounding muscles.

Orbital Exenteration

Exenteration involves removing the eye together with the surrounding orbital contents (muscles, fat, sometimes eyelids). It is reserved for aggressive cancers that involve the orbit and cannot be controlled by less extensive surgery. Reconstruction options — including skin flaps and orbital prostheses — are discussed in advance with oculoplastic and reconstructive surgeons.

Active Surveillance

Not every eye tumor needs immediate treatment. Some very small choroidal lesions, for example, may be classified as “choroidal nevus with low-risk features” and watched with regular imaging instead of being treated. Active surveillance is a legitimate strategy when the risks of treatment outweigh the likely benefit.

The Treatment Plan and What to Expect

A treatment plan in ocular oncology is built by a multidisciplinary team, which typically includes an ocular oncologist (an ophthalmologist with sub-specialty training), a radiation oncologist, a medical oncologist (and a paediatric oncologist for children), an oculoplastic surgeon, and pathologists. Decisions are often discussed at a tumor board, where the case is reviewed jointly.

Once the plan is agreed, what happens next depends on the modality. A general outline:

• For plaque brachytherapy: a short hospital admission (typically 4–7 days), with surgery to place the plaque, the radiation delivered while the plaque is in place, and a second short surgery to remove it.
• For local tumor surgery or eyelid surgery: often a day-case or short-stay admission under local or general anaesthesia, with reconstructive surgery either at the same time or planned shortly after.
• For enucleation: a 1–3 day hospital stay with the orbital implant placed during the same operation; prosthesis fitting follows around 4–6 weeks later.
• For systemic chemotherapy: a course of cycles spread over several months, typically as part of outpatient or day-care visits, with monitoring blood tests in between.
• For intra-arterial or intravitreal chemotherapy: repeated sessions over weeks to months, with general anaesthesia for younger children.
• For laser or cryotherapy: outpatient sessions, sometimes repeated, often combined with other treatments.

Throughout treatment, regular examinations under anaesthesia (in children) or in clinic (in adults) are used to assess how the tumor is responding and to decide on next steps.

Side Effects and How They Are Managed

Side effects depend heavily on the treatment used.

After Eye Surgery

Common short-term effects include pain, swelling, bruising, watering, and a feeling that something is in the eye. The eye may be patched for a period after surgery. Antibiotic and anti-inflammatory drops are used. Follow-up appointments check healing and intraocular pressure.

After Radiation Therapy

Plaque brachytherapy and external beam radiation can cause radiation retinopathy (damage to the retina’s blood vessels), radiation optic neuropathy, cataract, dry eye, and changes in vision that may develop months or years after treatment. These complications are monitored at follow-up and can sometimes be treated — for example, intravitreal injections for radiation retinopathy.

After Chemotherapy

Systemic chemotherapy can cause fatigue, nausea, hair loss, lowered blood counts (raising the risk of infection), and other effects depending on the specific drugs used. Children receiving systemic chemotherapy for retinoblastoma are monitored carefully for these effects. Intravitreal chemotherapy can cause local inflammation and may affect the retina.

After Enucleation

Healing of the socket takes several weeks. The orbital implant rarely — but sometimes — becomes exposed or infected and may need additional surgery. The prosthesis may need adjustment over time. Emotional adjustment to losing an eye is a significant part of recovery; many ocular oncology centres offer or refer to counselling support, and patient communities can be helpful.

After Laser or Cryotherapy

Localised inflammation, temporary changes in vision near the treated area, and (with cryotherapy) eyelid swelling are common in the short term. Most settle over days to weeks.

Visual changes after any treatment may include reduced sharpness, blind spots, double vision, glare, or changes in colour vision, depending on which part of the eye was affected. Low-vision rehabilitation services can help people make the most of remaining vision.

Response, Monitoring, and Follow-Up

Ongoing follow-up is essential in ocular oncology because some eye tumors can recur locally and some (especially uveal melanoma) carry a long-term risk of metastasis even after the eye tumor is controlled.

Follow-up typically includes:

• Regular ocular examinations with fundoscopy, imaging, and ultrasound to check for local recurrence and treatment-related effects
• Periodic systemic imaging — for uveal melanoma, liver imaging (ultrasound or MRI) every 6–12 months is commonly recommended, because the liver is the most frequent site of metastasis
• Hearing, kidney, and blood checks for patients who received chemotherapy, particularly children
• Second-eye screening for children with retinoblastoma, where the other eye remains at risk for years
• Skin and lymph-node checks in conjunctival melanoma and eyelid melanoma

How long surveillance continues depends on the tumor. For retinoblastoma, regular examinations of both eyes — often under anaesthesia in the early years — continue through childhood, with long-term monitoring for second cancers in genetically affected children. For uveal melanoma, lifelong follow-up is common because late metastasis can occur. For conjunctival and eyelid cancers, follow-up is usually intensive for the first 5 years and then less frequent.

Combining Ocular Tumor Management with Other Treatments

Ocular tumor care is rarely a single intervention. Combination strategies are the norm:

• Retinoblastoma: systemic chemotherapy to shrink the tumor, followed by focal treatments (laser, cryotherapy) for residual disease; intra-arterial or intravitreal chemotherapy as needed; enucleation reserved for advanced disease that cannot be controlled or where there is concern about spread along the optic nerve.
• Uveal melanoma: plaque brachytherapy or proton beam as primary local treatment, often with TTT as consolidation; enucleation for large tumors or when eye-sparing treatment is not possible; targeted therapy or immunotherapy under medical oncology if metastases develop.
• Conjunctival and ocular surface tumors: surgical excision with margins, often combined with topical chemotherapy or interferon, sometimes with cryotherapy to the edges of the excision; radiation in selected cases.
• Eyelid cancers: Mohs micrographic surgery or wide excision with frozen section control, followed by reconstructive surgery to restore eyelid function and appearance.
• Ocular and orbital lymphoma: radiation therapy or systemic chemotherapy under medical oncology, depending on whether the disease is isolated or part of systemic lymphoma.

Reconstructive and rehabilitative services — including oculoplastic reconstruction, prosthetic eye fitting, and low-vision support — are part of comprehensive care.

Ocular Tumor Management in Children

Modern retinoblastoma treatment aims to save life first, save the eye second, and preserve vision where possible. Survival outcomes are excellent in well-resourced settings — well above 95% in many series — provided diagnosis is timely and care is delivered through a specialised paediatric ocular oncology team.

Treatment combines:

• Systemic chemotherapy to shrink tumors
• Intra-arterial chemotherapy for advanced eyes in centres with this capability
• Intravitreal chemotherapy for vitreous seeding
• Laser therapy and cryotherapy for residual tumor
• Plaque brachytherapy in selected cases
• Enucleation when the eye cannot be salvaged or there is risk of spread

Children with bilateral or familial retinoblastoma are offered genetic testing because around 40% of cases involve a germline RB1 gene change. A positive result has implications for siblings, future children, and long-term surveillance for second cancers later in life. Genetic counselling is part of standard care in this setting.

Other tumors that affect children’s eyes include orbital rhabdomyosarcoma (a soft-tissue cancer that requires combined chemotherapy and radiation under paediatric oncology), optic pathway gliomas (often linked to neurofibromatosis type 1), and vascular tumors. Each has its own treatment pathway, usually run in close coordination with paediatric oncology services.

Support for the family — including practical help, school liaison, psychological support, and long-term follow-up — is recognised as a core part of paediatric ocular oncology, not an add-on.

Living During and After Treatment

The recovery experience varies widely depending on what treatment was given and how much vision is affected.

Vision Changes

Some patients retain good vision, particularly after small tumor treatment or for tumors away from the central retina. Others experience reduced vision in the treated eye, blind spots, or, after enucleation, loss of vision on one side. The brain adjusts over time to monocular vision; depth perception is affected but most daily activities, including driving in many places, are possible.

Cosmetic and Emotional Adjustment

For those who undergo enucleation or exenteration, the psychological adjustment can be significant. A well-fitted prosthesis is comfortable, blinks naturally, and resembles the other eye closely. Even so, the experience of losing an eye is real, and many people find that talking to a counsellor or to others who have been through similar treatment is helpful.

Returning to Work and Daily Life

Many adults return to work within a few weeks of localised treatment such as plaque brachytherapy. For those who have had enucleation, return depends on the nature of the work; jobs requiring fine depth perception (some surgical, dental, and driving roles) may need workplace assessment and adjustment.

Driving

Driving rules vary by country. After enucleation or significant vision loss in one eye, a period of adjustment is usually needed and a vision assessment may be required before resuming driving.

Sun and UV Protection

Ultraviolet exposure is linked to certain ocular surface and eyelid cancers and is thought to play a role in some intraocular cancers. Wearing UV-protective sunglasses and a wide-brimmed hat is sensible for everyone who has had an eye tumor, particularly those with a history of conjunctival or eyelid cancer.

Long-Term Health

Patients who received systemic chemotherapy or radiation are followed for late effects, including (for children) the long-term risk of second cancers. Healthy general habits — not smoking, balanced nutrition, regular exercise, and routine cancer screening appropriate for age — matter as much in this population as in any other.

Risks and Complications

Possible complications of ocular tumor management include:

• Vision loss, partial or complete, in the treated eye
• Cataract (clouding of the lens), particularly after radiation
• Glaucoma (raised eye pressure)
• Radiation retinopathy or optic neuropathy
• Dry eye, persistent watering, or eyelid changes
• Retinal detachment
• Bleeding inside the eye (vitreous haemorrhage)
• Infection
• Orbital implant exposure or movement (after enucleation)
• Cosmetic asymmetry
• Local tumor recurrence
• Spread of the cancer to other parts of the body (metastasis)
• For systemic chemotherapy — lowered blood counts, infection, organ-specific side effects, and (for some agents in children) long-term hearing or kidney effects

Each treatment plan weighs the chance of these complications against the need to control the tumor. Your ocular oncology team will go through the specific risks that apply to your situation.

Prognosis

Prognosis depends strongly on the type of tumor, its size, its biology, and whether it has spread at the time of diagnosis.

• Retinoblastoma, when treated promptly in well-resourced settings, has very high survival rates — commonly reported as above 95% in such settings.
• Uveal melanoma achieves high rates of local tumor control with plaque brachytherapy or proton beam therapy; long-term survival depends heavily on the genetic features of the tumor and on whether liver metastases develop, which is why long-term surveillance is important.
• Conjunctival melanoma can recur locally and requires close follow-up; outcomes depend on size, location, and completeness of excision.
• Eyelid skin cancers have generally good outcomes when treated early, with basal cell carcinoma having especially favourable prognosis.
• Ocular lymphoma outcomes depend on the type of lymphoma and whether systemic disease is present.

Personalised prognostic information is best discussed with your treating team, who can take into account your specific imaging, pathology, and genetic findings.

Frequently Asked Questions

Will I lose my eye?
Not necessarily. Many eye tumors today are treated with eye-sparing approaches such as plaque brachytherapy, laser, cryotherapy, chemotherapy, or local surgery. Enucleation is reserved for situations where saving the eye would compromise saving life. Whether the eye can be preserved depends on the tumor type, size, and location.

Will I lose my vision in the treated eye?
Vision outcomes vary. Some patients retain useful vision, especially when the tumor is small and away from the central retina or optic nerve. Others experience reduced vision over time. Your ocular oncologist can give you a realistic picture based on the specifics of your case.

What does a prosthetic eye look and feel like?
A modern custom prosthesis is hand-painted to match the other eye and is fitted to the orbital implant placed during surgery. It moves with the surrounding tissues and is comfortable to wear all day. It is removed periodically for cleaning. Most people adjust well to wearing a prosthesis.

Is eye cancer hereditary?
Some forms can be. Around 40% of retinoblastoma cases involve an inherited or germline change in the RB1 gene. Familial uveal melanoma is uncommon but exists, and some genetic syndromes raise the risk of certain eye tumors. Genetic counselling is offered where it is relevant to your situation.

Can eye tumors spread to other parts of the body?
Yes. Uveal melanoma in particular can spread to the liver years after successful treatment of the eye tumor, which is why long-term systemic surveillance is part of standard care. Retinoblastoma can spread along the optic nerve if untreated. Conjunctival and eyelid melanomas can spread to lymph nodes. The risk of spread depends on the tumor type and stage.

How long does follow-up continue?
For most eye cancers, follow-up continues for many years — often lifelong for uveal melanoma and for children treated for retinoblastoma. The frequency of visits decreases over time but does not usually stop entirely.

Can I fly or travel after eye tumor treatment?
In most cases, yes, once the immediate post-treatment period has passed and your treating team confirms it is safe. Specific advice depends on the type of treatment received. After certain intraocular surgeries, air travel may be restricted briefly because of pressure changes.

What lifestyle changes help after treatment?
UV protection through sunglasses and hats, not smoking, attention to general health, and attending all scheduled follow-up visits are sensible steps. Specific dietary supplements are not proven to change eye cancer outcomes, and major societies do not recommend them as a treatment.

What if the cancer comes back?
Recurrence is managed individually. Options may include further local treatment, additional radiation, systemic therapy, or enucleation if the eye can no longer be safely preserved. Newer targeted therapies and immunotherapies are expanding the options for advanced or metastatic disease, particularly for uveal melanoma.

Conclusion

Ocular tumor management is a careful balance between controlling cancer, preserving the eye, and protecting vision. Treatment is rarely a single procedure; it is a coordinated plan that combines microsurgery, radiation, laser, cryotherapy, and systemic therapy, chosen according to the type and stage of the tumor and personalised to the individual. For children with retinoblastoma and for adults with uveal melanoma, conjunctival tumors, eyelid cancers, and orbital tumors, the modern toolkit allows the eye to be preserved more often than in the past, and vision to be maintained in many early-stage cases.

What remains constant is the importance of timely diagnosis, accurate imaging and pathology, treatment in a centre with ocular oncology expertise, and committed long-term follow-up. Even where treatment requires removal of the eye, reconstructive and prosthetic care today produces good cosmetic and functional outcomes, and life after treatment can be full and active. The right plan for any individual is the one shaped jointly with their ocular oncology team, weighing tumor control against the goal of keeping as much of vision and quality of life as possible.